The ADHD Market's New Player: A Shift in Pharmaceutical Landscape The recent earnings call from Collegium Pharmaceutical, Inc.
has left investors and industry watchers abuzz with its aggressive expansion into the attention deficit hyperactivity disorder (ADHD) market.
Beneath this strategic shift lies a more nuanced story – one that speaks to the evolving dynamics of the pharmaceutical landscape.